Research Papers:

Selumetinib-based therapy in uveal melanoma patient-derived xenografts

Didier Decaudin, Rania El Botty, Béré Diallo, Gerald Massonnet, Justine Fleury, Adnan Naguez, Chloé Raymondie, Emma Davies, Aaron Smith, Joanne Wilson, Colin Howes, Paul D. Smit, Nathalie Cassoux, Sophie Piperno-Neumann, Sergio Roman-Roman and Fariba Némati _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:21674-21686. https://doi.org/10.18632/oncotarget.24670

Metrics: PDF 1406 views  |   HTML 2350 views  |   ?  


Didier Decaudin1,2, Rania El Botty1, Béré Diallo1, Gerald Massonnet1, Justine Fleury1, Adnan Naguez1, Chloé Raymondie1, Emma Davies3, Aaron Smith3, Joanne Wilson3, Colin Howes3, Paul D. Smith3, Nathalie Cassoux4, Sophie Piperno-Neumann2, Sergio Roman-Roman5 and Fariba Némati1

1Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University Paris, Paris, France

2Department of Medical Oncology, Institut Curie, Paris, France

3IMED Oncology, AstraZeneca, Cambridge, UK

4Department of Oncological Ophthalmology, Institut Curie, Paris, France

5Department of Translational Research, Institut Curie, PSL University Paris, Paris, France

Correspondence to:

Fariba Némati, email: [email protected]

Keywords: uveal melanoma; patient-derived xenografts; selumetinib; targeted therapies; pharmacodynamics

Received: September 19, 2017    Accepted: February 26, 2018    Published: April 24, 2018


The prognosis of metastatic uveal melanoma (UM) is among the worst of all human cancers. The identification of near-ubiquitous GNAQ/GNA11 mutations and the activation of MAPK signaling in UM have raised hopes of more effective, targeted therapies, based on MEK inhibition, for example. We evaluated the potential of drug combinations to increase the efficacy of the MEK inhibitor selumetinib (AZD6244, ARRY-142886), in UM cell lines and Patient-Derived Xenografts. We first evaluated the combination of selumetinib and DTIC. We found that DTIC did not improve the in vitro or in vivo antitumor efficacy of selumetinib, consistent with the outcome of the SUMIT clinical trial assessing the efficacy of this combination in UM. We then tested additional selumetinib combinations with the chemotherapy agent docetaxel, the ERK inhibitor AZ6197, and the mTORC1/2 inhibitor, vistusertib (AZD2014). Combinations of selumetinib with ERK and mTORC1/2 inhibitors appeared to be the most effective in UM PDX models.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24670